Last reviewed · How we verify
DHP
DHP is a dihydropyridine calcium channel blocker that works by relaxing blood vessels and reducing blood pressure.
DHP is a dihydropyridine calcium channel blocker that works by relaxing blood vessels and reducing blood pressure. Used for Hypertension, Angina pectoris.
At a glance
| Generic name | DHP |
|---|---|
| Sponsor | Centro de Investigacao em Saude de Manhica |
| Drug class | calcium channel blocker |
| Target | L-type calcium channels |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | FDA-approved |
Mechanism of action
DHP acts on the L-type calcium channels in vascular smooth muscle cells, leading to vasodilation and decreased peripheral resistance. This results in a decrease in blood pressure and a reduction in the workload on the heart.
Approved indications
- Hypertension
- Angina pectoris
Common side effects
- Edema
- Headache
- Dizziness
- Fatigue
Key clinical trials
- A 12-Week Treatment Study to Evaluate the Effectiveness of Albuterol Multidose Dry Powder Inhaler With Integrated Electronic Module Digital System (eMDPI DS) in Participants13 Years or Older With Asthma (PHASE4)
- Efficacy of Early Rhythm Control Therapy in Patients With Subclinical Atrial Fibrillation (NA)
- Catheter Ablation Versus Anti-arrhythmic Drugs for Premature Ventricular Complexes (NA)
- Treating Atrial Fibrillation in Heart Failure With Preserved Ejection Fraction: Ablation or Medication (NA)
- Propofol-Only Versus Dexmedetomidine-Propofol in Children Undergoing Magnetic Resonance Imaging (PHASE4)
- Safety and Efficacy of Polymyxin B Hemoperfusion (PMX) for Endotoxemic Septic Shock in a Randomized, Open-Label Study (NA)
- A Prospective Registry Study to Assess Real-world Patient Characteristics, Treatment Patterns, and Longitudinal Outcomes in Patients Receiving Mavacamten and Other Treatments for Symptomatic Obstructive Hypertrophic Cardiomyopathy (Obstructive-HCM)
- Data Analysis for Drug Repurposing for Effective Alzheimer's Medicines (DREAM)- Dihydropyridine Calcium Channel Blockers Versus Hydrochlorothiazide
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- DHP CI brief — competitive landscape report
- DHP updates RSS · CI watch RSS
- Centro de Investigacao em Saude de Manhica portfolio CI